Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer.

MLA

Bocanegra, Ana, et al. “Plasma Fractalkine Contributes to Systemic Myeloid Diversity and PD-L1/PD-1 Blockade in Lung Cancer.” EMBO Reports, vol. 24, no. 8, Aug. 2023, p. e55884. EBSCOhost, https://doi.org/10.15252/embr.202255884.

APA

Bocanegra, A., Fernández-Hinojal, G., Ajona, D., Blanco, E., Zuazo, M., Garnica, M., Chocarro, L., Alfaro-Arnedo, E., Piñeiro-Hermida, S., Morente, P., Fernández, L., Remirez, A., Echaide, M., Martinez-Aguillo, M., Morilla, I., Tavira, B., Roncero, A., Gotera, C., Ventura, A., … Kochan, G. (2023). Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer. EMBO Reports, 24(8), e55884. https://doi.org/10.15252/embr.202255884

Chicago

Bocanegra, Ana, Gonzalo Fernández-Hinojal, Daniel Ajona, Ester Blanco, Miren Zuazo, Maider Garnica, Luisa Chocarro, et al. 2023. “Plasma Fractalkine Contributes to Systemic Myeloid Diversity and PD-L1/PD-1 Blockade in Lung Cancer.” EMBO Reports 24 (8): e55884. doi:10.15252/embr.202255884.